Chemotherapy, trastuzumab, and pathological complete response: When shall we three meet again?

Journal of Clinical Oncology

Volumn 29, Issue 25, 2011, Pages 3344-3346

  Cameron, David A ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; LAPATINIB; PACLITAXEL; PERTUZUMAB; TRASTUZUMAB;

ADJUVANT THERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; DISEASE FREE SURVIVAL; EARLY CANCER; EDITORIAL; HUMAN; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREOPERATIVE TREATMENT; PRIORITY JOURNAL; TUMOR VOLUME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; NEOADJUVANT THERAPY; RECEPTOR, ERBB-2;

EID: 80052779427     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.37.0817     Document Type: Editorial

References (22)

1. Bonadonna G, Valagussa P, Brambilla C, et al: Primary chemotherapy in operable breast cancer: Eight-year experience at the Milan Cancer Institute. J Clin Oncol 16:93-100, 1998 (Pubitemid 28041584)
2. Vecchio FM, Valentini V, Minsky BD, et al: The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. Int J Radiat Oncol Biol Phys 62:752-760, 2005 (Pubitemid 40779765)
3. Untch M, Fasching PA, Konecny GE, et al: Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: Results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol 29:3351-3357, 2011
4. Bear HD, Anderson S, Smith RE, et al: Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24:2019-2027, 2006 (Pubitemid 46622110)
5. Kuroi K, Toi M, Tsuda H, et al: Unargued issues on the pathological assessment of response in primary systemic therapy for breast cancer. Biomed Pharmacother 59:S387-S392, 2005 (suppl 2)
6. Ogston KN, Miller ID, Payne S, et al: A new histological grading system to assess response of breast cancers to primary chemotherapy: Prognostic significance and survival. Breast 12:320-327, 2003 (Pubitemid 37322062)
7. Christensen D: The Will Rogers phenomenon: Roping the effects of a new cancer staging system. J Natl Cancer Inst 95:1105-1106, 2003
8. Symmans WF, Peintinger F, Hatzis C, et al: Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25:4414-4422, 2007 (Pubitemid 350013847)
9. Untch M, Rezai M, Loibl S, et al: Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: Results from the GeparQuattro study. J Clin Oncol 28:2024-2031, 2010
10. Untch M, Loibl S, Bischoff J, et al: Lapatinib vs trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy: Primary efficacy endpoint analysis of the GEPARQUINTO study (GBG 44). Cancer Res 70:81s, 2010 (abstr S3-1), 2011
11. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001 (Pubitemid 32222155)
12. Ryberg M, Nielsen D, Skovsgaard T, et al: Epirubicin cardiotoxicity: An analysis of 469 patients with metastatic breast cancer. J Clin Oncol 16:3502-3508, 1998 (Pubitemid 28506760)
13. Pentassuglia L, Graf M, Lane H, et al: Inhibition of ErbB2 by receptor tyrosine kinase inhibitors causes myofibrillar structural damage without cell death in adult rat cardiomyocytes. Exp Cell Res 315:1302-1312, 2009
14. Pinder MC, Duan Z, Goodwin JS, et al: Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 25:3808-3815, 2007 (Pubitemid 47477254)
15. Bozovic-Spasojevic I, Azim HA Jr, Paesmans M, et al: Neoadjuvant anthracycline and trastuzumab for breast cancer: Is concurrent treatment safe? Lancet Oncol 12:209-211, 2011
16. Baselga J, Bradbury I, Eidtmann H, et al: First results of the NeoALTTO Trial (BIG 01-06 / EGF 106903): A phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer. Cancer Res 70:82s, 2010 (abstr S3-3)
17. Gianni L, Pienkowski T, Im YH, et al: Neoadjuvant pertuzumab (P) and trastuzumab (H): Antitumor and safety analysis of a randomized phase II study ('NeoSphere'). Cancer Res 70:82s, 2010 (abstr S3-2)
18. Sparano JA, Wang M, Martino S, et al: Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358:1663-1671, 2008 (Pubitemid 351549913)
19. Costa RB, Kurra G, Greenberg L, et al: Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer. Ann Oncol 21:2153-2160, 2010
20. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005 (Pubitemid 41464706)
21. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005 (Pubitemid 41464705)
22. Gianni L, Eiermann W, Semiglazov V, et al: Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375:377-384, 2010